🔍

JYOTHYLAB - Jyothy Labs

📊 NSE: JYOTHYLAB 🏢 Personal Care - Indian 📅 Last Updated: 12/14/2025 8:44

📢 Recent Corporate Announcements

Jyothy Labs FY26 Revenue Up 3.5% to ₹2,944 Cr; PAT Declines 10% Amid Margin Pressure

🔵 WATCH ⭐ 8/10

EARNINGS 📅 04 May 2026, 03:10 PM

Jyothy Labs reported a modest 3.5% revenue growth for FY26, reaching ₹2,944 crores, while Q4 revenue grew 7.7% supported by a robust 10.8% volume growth. However, profitability was significantly impacted by rising input costs, with FY26 PAT declining 10.2% to ₹333.2 crores and EBITDA margins contracting to 15.3% from 17.6%. The company maintains a strong balance sheet with a cash balance of ₹997 crores and an efficient working capital cycle of 15 days. Management has signaled a strategy of prioritizing volume growth over margins in the near term due to persistent inflation in crude-linked derivatives.

FY26 Revenue grew 3.5% to ₹2,944 crores with 6% volume growth; Q4 volume growth was higher at 10.8%.
FY26 PAT decreased by 10.2% to ₹333.2 crores, while Q4 PAT fell 12.3% to ₹67.5 crores.
Operating EBITDA margin contracted to 15.3% for FY26 compared to 17.6% in the previous year due to input cost inflation.
Fabric Care and Dishwash segments showed strong Q4 momentum, growing by 14.4% and 20.1% respectively.
Cash and bank balances increased to ₹997 crores, providing significant liquidity for future expansions.

💡 Investors should monitor the company's ability to implement price hikes to offset input cost inflation, as margins are currently under pressure despite healthy volume growth. The strong cash position and market share gains are positive, but near-term earnings may remain volatile until raw material prices stabilize.

Jyothy Labs Q4 Revenue Up 7.7% to ₹717 Cr; Strong 10.8% Volume Growth

🟡 NEUTRAL ⭐ 8/10

EARNINGS 📅 04 May 2026, 03:05 PM

Jyothy Labs reported a robust 10.8% volume growth in Q4 FY26, significantly outperforming its value growth of 7.7% as revenue reached ₹717 crore. While the Fabric Care and Personal Care segments saw double-digit growth, EBITDA margins for the quarter compressed to 13.5% due to rising input costs and crude-linked inflation. For the full year FY26, the company recorded a revenue of ₹2,944 crore and a PAT of ₹333.2 crore. The company remains debt-free and has recommended a final dividend of ₹3.5 per share.

Q4 FY26 volume growth stood at 10.8% vs value growth of 7.7%, indicating aggressive market share pursuit.
Fabric Care segment delivered exceptional performance with 17.8% volume growth in Q4 FY26.
Personal Care segment revenue surged 20.1% in Q4, aided by GST rate reductions and a Margo brand relaunch.
Operating EBITDA margin for Q4 was 13.5%, impacted by West Asia developments and input cost inflation.
The Board recommended a final dividend of ₹3.5 per share for the financial year ended March 31, 2026.

💡 Investors should focus on the strong volume recovery which indicates brand strength, while monitoring the company's ability to pass on input cost hikes to protect margins in FY27. The stock remains a solid defensive play given its debt-free status and consistent dividend payout.

Jyothy Labs Recommends ₹3.50 Dividend; FY26 Net Profit Declines to ₹333.19 Crore

🟡 NEUTRAL ⭐ 8/10

EARNINGS 📅 04 May 2026, 02:58 PM

Jyothy Labs Limited has announced a final dividend of ₹3.50 per share for FY 2025-26, with the record date fixed as June 29, 2026. For the full financial year, the company reported a modest revenue growth of 3.5% reaching ₹2,944.29 crore, though net profit declined by 10.2% to ₹333.19 crore compared to the previous year. The fourth quarter saw a revenue increase to ₹717.41 crore, but profitability remained under pressure with a year-on-year profit dip of 12.3%.

Recommended a final dividend of ₹3.50 per equity share of face value ₹1 each.
Annual revenue from operations increased to ₹2,944.29 crore in FY26 from ₹2,843.92 crore in FY25.
Net profit for FY26 decreased to ₹333.19 crore compared to ₹371.17 crore in the previous fiscal.
Q4 FY26 revenue grew 7.7% YoY to ₹717.41 crore, while Q4 net profit fell to ₹67.52 crore.
Record date for dividend entitlement is June 29, 2026, with payment scheduled on or after July 14, 2026.

💡 Investors should monitor the company's margin performance as profitability has declined despite revenue growth. The ₹3.50 dividend provides a decent yield, but the contraction in annual EPS from ₹10.11 to ₹9.07 warrants a cautious outlook on cost management.

Jyothy Labs Recommends Rs 3.50 Dividend; FY26 Net Profit Declines 10.2% to Rs 333 Crore

🟡 NEUTRAL ⭐ 8/10

DIVIDEND 📅 04 May 2026, 02:54 PM

Jyothy Labs has recommended a final dividend of Rs 3.50 per share for FY 2025-26, with a record date set for June 29, 2026. While the company achieved a modest 3.5% growth in annual revenue to Rs 2,944 crore, the full-year net profit declined by 10.2% to Rs 333.2 crore. For the final quarter (Q4FY26), revenue grew 7.7% YoY, but net profit fell 12.3% to Rs 67.5 crore due to higher material costs and tax adjustments. The dividend payout remains a key positive for shareholders despite the earnings pressure.

Recommended a final dividend of Rs 3.50 per equity share of face value Re 1 for FY 2025-26.
Annual revenue from operations increased by 3.5% YoY to Rs 2,94,429 Lakhs.
Full-year net profit decreased to Rs 33,319 Lakhs from Rs 37,117 Lakhs in the previous fiscal year.
Q4 FY26 net profit stood at Rs 6,752 Lakhs, a decline of 12.3% compared to Rs 7,700 Lakhs in Q4 FY25.
Record date for dividend entitlement is June 29, 2026, with payment scheduled on or after July 14, 2026.

💡 Investors should monitor the margin compression as material costs rose significantly despite revenue growth. While the dividend yield is attractive, the decline in EPS from Rs 10.11 to Rs 9.07 warrants a cautious approach regarding bottom-line recovery.

Jyothy Labs FY26 Net Profit Declines 10.2% to ₹333 Cr; Final Dividend of ₹3.50 Declared

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 04 May 2026, 02:52 PM

Jyothy Labs reported a mixed performance for the financial year ended March 31, 2026, with annual revenue growing 3.5% YoY to ₹2,944 crore. However, net profit for the full year saw a 10.2% decline to ₹333 crore, primarily due to rising material costs and higher tax expenses. For the final quarter (Q4FY26), revenue grew 7.7% YoY, but profitability was hit by a tax adjustment of ₹10.64 crore related to earlier periods. Despite the profit dip, the board has recommended a final dividend of ₹3.50 per share.

Annual Revenue from operations increased 3.5% YoY to ₹2,94,429 Lakhs in FY26.
Full-year Net Profit fell 10.2% to ₹33,319 Lakhs from ₹37,117 Lakhs in the previous year.
Q4FY26 Net Profit declined 12.3% YoY to ₹6,752 Lakhs, impacted by higher material costs and tax adjustments.
Board recommended a final dividend of ₹3.50 per equity share (350% of face value) with a record date of June 29, 2026.
Cost of materials consumed rose 8.3% for the full year, putting pressure on operating margins.

💡 Investors should be cautious regarding the margin pressure caused by rising input costs, though the steady dividend provides some yield support. Monitor the company's volume growth and pricing power in upcoming quarters to see if profitability stabilizes.

Jyothy Labs Estimates ₹7.33 Crore Inventory Loss from Punjab Warehouse Fire

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 02 May 2026, 03:58 PM

Jyothy Labs has provided an update on a fire incident that occurred at its C&FA-operated warehouse in Patiala, Punjab, on April 29, 2026. The company estimates the value of the affected inventory at approximately ₹7.33 crore. Management confirmed that the fire was brought under control on the same day and that the inventory is covered under existing insurance policies. The insurance claim process has been initiated, and the final recovery will depend on the insurer's assessment.

Fire incident occurred at the Patiala, Punjab warehouse on April 29, 2026.
Estimated value of inventory affected by the fire is approximately ₹7.33 crore.
Inventory is fully covered under insurance policies, and the claim process is underway.
The fire was successfully brought under control on the day of the incident.
The amount recoverable is subject to assessment and approval by the insurance provider.

💡 Investors should note that the financial impact is relatively small compared to the company's annual turnover and is expected to be largely mitigated by insurance. No significant impact on the stock price or long-term operations is anticipated.

Jyothy Labs Reports Fire at Punjab Warehouse; No Material Impact on Operations Anticipated

🔵 WATCH ⭐ 4/10

OTHER 📅 29 Apr 2026, 06:12 PM

Jyothy Labs Limited reported a fire incident at its C&FA operated warehouse in Patiala, Punjab, on April 29, 2026. The fire originated from an adjacent property and spread to the company's facility, but no human casualties or injuries were reported. The company has confirmed that it maintains adequate insurance coverage and has already notified the insurance provider for a survey and loss assessment. Management explicitly stated that they do not expect any material impact on the company's overall operations or financial performance.

Fire occurred at 6:30 A.M. on April 29, 2026, at the Patiala warehouse facility.
Zero injuries or loss of life reported following the incident.
Loss assessment is currently underway with adequate insurance coverage in place to mitigate financial impact.
Management anticipates no material impact on the company's broader business operations or activities.

💡 Investors should monitor for any follow-up disclosures regarding the final loss amount and insurance settlement, though no immediate action is required given the lack of operational disruption.

Jyothy Labs Schedules Q4FY26 Earnings Conference Call for May 4, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 27 Apr 2026, 01:13 PM

Jyothy Labs Limited has announced its conference call for analysts and investors to be held on May 4, 2026, at 16:00 IST. The call is intended to discuss the company's audited financial results for the quarter and full year ended March 31, 2026. Management will provide insights into the financial performance and the strategic 'way forward' for the company. This is a standard post-earnings engagement coordinated by ICICI Securities.

Conference call scheduled for May 4, 2026, at 4:00 PM IST.
Focus on audited financial results for the quarter and full year ended March 31, 2026.
Universal dial-in numbers provided: +91 22 6280 1144 and +91 22 7115 8045.
International toll-free access available for Singapore, Hong Kong, UK, and USA.
Diamond Pass registration link provided for priority access to the call.

💡 Investors should review the audited financial results once released on the exchange and listen to the call for management's commentary on volume growth and margin outlook.

Jyothy Labs to Close Trading Window from April 1, 2026, for Q4 and FY26 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 26 Mar 2026, 03:03 PM

Jyothy Labs Limited has announced the closure of its trading window for all designated persons and their immediate relatives starting April 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the announcement of financial results for the fourth quarter and the full financial year ending March 31, 2026. The window will remain closed until 48 hours after the results are declared to the public. This is a standard regulatory procedure to prevent insider trading during the period when sensitive financial information is being finalized.

Trading window closure effective from Wednesday, April 1, 2026.
Closure pertains to the financial results for the quarter and year ending March 31, 2026.
Restriction applies to all designated persons and their immediate relatives as per company code.
Trading window will reopen 48 hours after the public announcement of the financial results.

💡 No action is required as this is a routine regulatory filing. Investors should look out for the upcoming earnings announcement date to evaluate the company's quarterly performance.

Jyothy Labs to Hold One-on-One Meeting with Nalanda Capital on March 20, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 17 Mar 2026, 04:54 PM

Jyothy Labs Limited has scheduled a one-on-one meeting with Nalanda Capital on March 20, 2026. This disclosure is a routine filing under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has explicitly stated that no Unpublished Price Sensitive Information (UPSI) will be shared during this interaction. Investors are encouraged to review the latest presentation available on the company's website for current operational insights.

One-on-one meeting scheduled with Nalanda Capital for March 20, 2026
Compliance with SEBI (LODR) Regulations, 2015, specifically Regulation 30
Company confirms no Unpublished Price Sensitive Information (UPSI) will be disclosed
Latest investor presentation remains the primary source of shared information

💡 No immediate action is required as this is a routine investor interaction. Investors should monitor for any subsequent updates to investor presentations or management commentary following the meet.

Jyothy Labs to Meet Mirabilis Investment Trust on March 12, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 10 Mar 2026, 04:56 PM

Jyothy Labs Limited has scheduled a one-on-one meeting with Mirabilis Investment Trust on March 12, 2026. This interaction is part of the company's regular engagement with institutional investors and analysts. The company has explicitly stated that no Unpublished Price Sensitive Information (UPSI) will be shared during this meeting. Investors are encouraged to review the latest investor presentation available on the company's official website for current business insights.

One-on-one meeting scheduled with Mirabilis Investment Trust on March 12, 2026.
Disclosure made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Company confirms that no Unpublished Price Sensitive Information (UPSI) will be disclosed.
The schedule is subject to change based on exigencies from either the investor or the company.

💡 This is a routine investor interaction; no immediate action is required. Investors should monitor the company's website for any updated investor presentations following the meet.

Jyothy Labs to Meet Renaissance Investment Managers on March 6, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 25 Feb 2026, 12:43 PM

Jyothy Labs Limited has announced a scheduled one-on-one meeting with Renaissance Investment Managers on March 6, 2026. This disclosure is part of the company's routine regulatory compliance under SEBI (LODR) Regulations, 2015. The company has explicitly stated that no Unpublished Price Sensitive Information (UPSI) will be shared during this interaction. Such meetings are standard practice for listed companies to engage with institutional investors regarding publicly available information.

One-on-one meeting scheduled with Renaissance Investment Managers on March 6, 2026.
Compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Company confirmed that no Unpublished Price Sensitive Information (UPSI) will be disclosed.
Latest investor presentation remains available on the company's official website for public access.

💡 No immediate action is required as this is a routine investor engagement. Investors may review the latest investor presentation on the company's website for current business performance insights.

Jyothy Labs Schedules One-on-One Meeting with Pari Washington for Feb 26, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 24 Feb 2026, 02:44 PM

Jyothy Labs Limited has announced a scheduled one-on-one meeting with Pari Washington Company Advisors Pvt. Ltd on February 26, 2026. This disclosure is made in compliance with SEBI Regulation 30 regarding investor interactions. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during the meeting. Investors are encouraged to review the latest investor presentation available on the company's official website for current business insights.

One-on-one meeting scheduled with Pari Washington Company Advisors Pvt. Ltd on February 26, 2026
Compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Company confirms that no Unpublished Price Sensitive Information (UPSI) will be disclosed
Latest investor presentation remains the primary source of shared information for the public

💡 No immediate action is required as this is a routine investor engagement. Investors should monitor for any subsequent corporate presentations that might provide updated business outlooks.

Jyothy Labs Schedules One-on-One Meeting with Mirae Asset Multicap Fund

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 23 Feb 2026, 06:05 PM

Jyothy Labs Limited has informed the exchanges about a scheduled one-on-one meeting with Mirae Asset Multicap Fund on February 25, 2026. The meeting is part of the company's regular investor engagement process and will be attended by company representatives. The management has clarified that no unpublished price sensitive information (UPSI) will be shared during the discussion. This notification is a standard compliance requirement under SEBI Listing Obligations and Disclosure Requirements.

Meeting scheduled with Mirae Asset Multicap Fund for February 25, 2026
Interaction type is specified as a one-on-one meeting
Company confirms no Unpublished Price Sensitive Information (UPSI) will be shared
Notification issued on February 23, 2026, in compliance with SEBI Regulation 30

💡 No immediate action is required as this is a routine institutional meeting. Investors may review the latest investor presentation on the company's website for current business insights.

Jyothy Labs Q3 FY26: Revenue Up 5.1% to ₹740 Cr; Volume Growth Strong at 7.2%

🟡 NEUTRAL ⭐ 8/10

EARNINGS 📅 13 Feb 2026, 12:24 PM

Jyothy Labs reported a 5.1% YoY revenue growth to ₹740 crores for Q3 FY26, supported by a healthy 7.2% volume growth. While Fabric Care and Personal Care segments performed well, the Dishwash segment saw a 1.3% value decline despite 7% volume growth due to aggressive pricing and promotions. Gross margins contracted by 330 bps to 46.5% because of rising input costs like LABSA and SLES, alongside MRP reductions. The company has divested its Bangladesh JV to focus on domestic growth and expects the Household Insecticide segment to turn around by FY27.

Revenue for Q3 FY26 stood at ₹740 crores with a volume growth of 7.2% and value growth of 5.1%.
Gross margin declined by 330 basis points to 46.5% due to raw material inflation and competitive pricing.
Fabric Care segment grew 9.2% in value, while Household Insecticides saw a 12.6% value growth driven by liquid vaporizers.
Dishwash segment volume grew 7% but value declined 1.3% due to higher grammage and price cuts.
Divested stake in Bangladesh JV (JKBL) with a loss of ₹4 crores to focus on core domestic and select export markets.

💡 Investors should focus on the company's ability to maintain volume momentum while navigating gross margin pressures from raw material volatility. The strategic shift in the Household Insecticide segment toward liquid vaporizers is a key monitorable for long-term profitability.

View All JYOTHYLAB Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

In FY 2024-25, Fabric Care grew 5.0% (44% of revenue), Dishwashing grew 3.7% (34% of revenue), Household Insecticides declined 6.5% (7% of revenue), Personal Care declined 0.9% (11% of revenue), and Others grew 10.8% (4% of revenue). For H1 FY26, the company reported 1% value growth and 3.2% volume growth.

Geographic Revenue Split

Not disclosed in available documents, though the company maintains a pan-India presence with 23 manufacturing facilities and a strong focus on rural-driven growth.

Profitability Margins

Gross margin for H1 FY26 stood at 48%, a contraction from 50.8% in H1 FY25 due to input cost pressures. PAT margin for FY24 was 13.3% (INR 369.3 Cr on INR 2,767.2 Cr revenue).

EBITDA Margin

Operating EBITDA margin was 17.5% in FY25 (INR 500 Cr) compared to 17.4% in FY24 (INR 480 Cr). However, H1 FY26 saw a decline to 16.3% from 18.4% in the previous year due to higher operating costs and commodity fluctuations.

Capital Expenditure

The company is expected to remain debt-free as there are no major debt-funded capital expenditure plans. Cash and bank balances including investments increased to INR 757 Cr in FY25 from INR 618 Cr in FY24.

Credit Rating & Borrowing

CARE Ratings reaffirmed 'CARE AA; Stable' for long-term bank facilities (INR 250 Cr) and 'CARE A1+' for Commercial Paper (INR 100 Cr, later withdrawn as unutilized). The company operates with minimal finance costs of INR 6 Cr (FY25).

⚙️ Operational Drivers

Raw Materials

Key inputs include chemicals for detergents (Fabric Care), raw materials for soaps (Personal Care), and materials for insecticide coils. Specific commodity names like palm oil or LAB are not explicitly listed but are categorized as 'input costs' and 'commodities'.

Capacity Expansion

The company operates 23 state-of-the-art manufacturing facilities across India. Specific MTPA capacity figures or planned expansion units are not detailed in the provided text.

Raw Material Costs

Cost of Goods Sold (COGS) was INR 1,419 Cr in FY25, representing 49.8% of revenue, a slight increase of 1.1% YoY from INR 1,404 Cr.

Manufacturing Efficiency

The company focuses on economies of scale and productivity improvements to balance competitive pricing with profitability.

Logistics & Distribution

Advertisement and sales promotion costs were INR 240 Cr in FY25 (8.4% of net sales), used to support a distribution network reaching 1.2 million outlets directly.

📈 Strategic Growth

Expected Growth Rate

3.20%

Growth Strategy

Growth will be driven by volume-led expansion in rural markets using the van/moped model, scaling premium product launches, and leveraging digital/modern trade channels. The company aims to maintain an EBITDA margin of 16-17% through better mix management and scaling innovations.

Products & Services

Fabric whiteners, detergent powders, detergent bars, liquid detergents, dishwash bars, dishwash liquids, household insecticide coils, and personal care soaps.

Brand Portfolio

Ujala, Maxo, Exo, Henko, Pril, Margo, and Mr. White.

New Products/Services

Focus on liquid detergents (main growth driver for Fabric Care) and organic/natural products developed through R&D.

Market Expansion

Expansion of direct reach to 1.2 million outlets and total availability in 2.8 million outlets, focusing on rural-driven growth and modern trade/e-commerce.

Market Share & Ranking

Ujala commands a dominant position in the fabric care (whitener) segment; the company is a prominent pan-India FMCG player.

Strategic Alliances

Merged Jyothy Fabricare Services Ltd (JFSL) into the parent company and divested its 75% equity stake in Jyothy Kallol Bangladesh Limited (JKBL) as of March 25, 2025.

🌍 External Factors

Industry Trends

The FMCG sector is seeing a measured recovery driven by affordability and easing cost pressures, with a shift toward digital channels and premiumization.

Competitive Landscape

Operates in a fiercely competitive and price-sensitive industry dominated by MNCs with larger diversified portfolios.

Competitive Moat

Strong brand equity (Ujala), a massive distribution network (2.8m outlets), and a debt-free balance sheet provide a durable competitive advantage against smaller players.

Macro Economic Sensitivity

Highly sensitive to rural sentiment and inflation; a median population age of 27 and government financial inclusion initiatives are expected to drive exponential consumption growth.

Consumer Behavior

Increasing consumerism and rising aspirations among India's young population are driving demand for cleaning and hygiene solutions.

Geopolitical Risks

Global uncertainties continue to pose challenges to input costs and supply chain stability.

⚖️ Regulatory & Governance

Industry Regulations

Impacted by GST rate revisions (September 2025) which caused a 13% advantage for some distributors through input credit but disrupted short-term market flow.